Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agile Therapeutics (AGRX – Research Report), Argenx Se (ARGX – Research Report) and Liminal BioSciences (LMNL – Research Report).
Agile Therapeutics (AGRX)
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Agile Therapeutics, with a price target of $2.50. The company’s shares closed last Wednesday at $0.34, close to its 52-week low of $0.34.
According to TipRanks.com, Livnat is a 1-star analyst with an average return of
Agile Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $2.83.
See Insiders’ Hot Stocks on TipRanks >>
Argenx Se (ARGX)
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Argenx Se, with a price target of $400.00. The company’s shares closed last Wednesday at $278.72.
According to TipRanks.com, Tsao is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $380.69 average price target, which is a 33.9% upside from current levels. In a report issued on January 7, Piper Sandler also maintained a Buy rating on the stock with a $375.00 price target.
Liminal BioSciences (LMNL)
In a report released today, Edwin Zhang from H.C. Wainwright reiterated a Hold rating on Liminal BioSciences. The company’s shares closed last Wednesday at $1.10, close to its 52-week low of $0.88.
According to TipRanks.com, Zhang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Liminal BioSciences.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AGRX:
- Wells Fargo Thinks Precigen’s Stock is Going to Recover
- Berenberg Bank Keeps Their Hold Rating on Five Below (FIVE)
- Microsoft vs. Apple: Which Stock is Headed for Growth in 2022?
- PUMA SE NPV (PMMAF) Gets a Buy Rating from RBC Capital
- Barrick Achieves Third Consecutive Annual Production Target; Shares Jump
